English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

This editorial refers to ‘A single infusion of MDCO-216 (ApoA-I Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease’, by D.G. Kallend et al. , on page 23. Apolipoprotein A-I (apoA-I) is the major protein component of the high-density lipoprotein (HDL) particles. Higher levels of apoA-I have been associated with a lower cardiovascular risk even among subjects with reduced low-density lipoprotein cholesterol (LDL-C) levels;1,2 but, unlike HDL-C, an increase in apoA-I levels in individuals treated with statins has been associated with a lower risk of major cardiovascular events.2 These and other data have encouraged investigations of apoA-I mimetic compounds or reconstituted HDL particles as a potential therapeutic strategy. ApoA-I Milano (apoA-IM) is a natural variant of human apoA-I identified in individuals in northern Italy, which results from the replacement of arginine by cysteine at position 173 of the apoA-I amino acid sequence;3 this variation introduces structural changes in apoA-I, allows the formation of apoA-I homodimers (A-IM/A-IM) and heterodimers with apoA-II, and alters the apoA-I properties, which ultimately may affect HDL function.3 The carriers of this variant usually exhibit a lipid phenotype consistent of …

Promoting high-density lipoprotein function via intravenous infusion: the rebirth of apoA-I Milano?